Nom du produit:1-(bromomethyl)-2-chlorobenzene
IUPAC Name:1-(bromomethyl)-2-chlorobenzene
- CAS：611-17-6
- Formule moléculaire：C7H6BrCl
- Pureté：95%+
- Numéro de catalogue：CM377530
- Poids moléculaire：205.48
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:611-17-6
- Formule moléculaire:C7H6BrCl
- Point de fusion:-
- Code SMILES:ClC1=C(CBr)C=CC=C1
- Densité:
- Numéro de catalogue:CM377530
- Poids moléculaire:205.48
- Point d'ébullition:
- N° Mdl:
- Stockage:
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- ALX-001
- Allyx Therapeutics has announced that the first patient has been dosed with its lead compound, ALX-001, in a new clinical study assessing safety, pharmacokinetics and potential therapeutic response in patients with Parkinson’s disease. ALX-001 (previously BMS-984923) is a silent allosteric modulator of mGluR5, and is a first-in-class compound that selectively blocks the pathogenic activation of the receptor while preserving the normal physiological glutamate signaling that is required for cognition. As such, ALX-001 has a wide therapeutic window that can saturate receptors while avoiding on-target toxicity observed with negative allosteric modulators. mGluR5 has been shown to be essential for mediating synaptic dysfunction and loss caused by multiple misfolded extracellular protein species, and as such, presents a novel approach for treating Alzheimer’s and Parkinson’s disease.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.
Recherche 
+86 21 5895 0110 
